Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Insights into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) phenotypes through comprehensive metabolomics (part III)) (Study ST000802)

Reversed phase NEGATIVE ION MODE (Analysis AN001274)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8
13-KODE	ME218836	0.34	1.12	0.18	0.24	0.49	1.03	4.55	3.09
9-KODE	ME218837	0.32	1.12	0.16	0.22	0.51	1.10	3.91	3.16
12(13)Ep-9-KODE	ME218841	0.49	1.31	0.53	0.36	0.77	0.95	2.51	1.94
5S,15R-diHETE	ME218814	0.65	1.03	NA	1.19	0.50	0.90	3.01	2.00
8,15-DiHETE	ME218813	0.34	1.11	0.13	0.84	0.48	1.06	4.63	1.66
Alpha-9(10)-EpODE	ME218845	0.51	1.17	0.12	0.34	0.64	1.17	3.93	1.47
13S-HODE	ME218818	0.47	1.21	0.24	0.59	0.70	1.02	3.85	1.69
9-HODE	ME218819	0.48	1.18	0.24	0.59	0.69	1.03	3.97	1.71
15,16-EpODE	ME218844	0.56	1.11	0.07	0.93	0.68	1.38	4.35	0.21
LTB4	ME218816	0.61	1.06	NA	0.33	0.73	0.93	3.12	0.47
11-HETE	ME218826	0.75	1.07	0.33	0.58	0.73	1.16	3.74	0.83
9-HETE	ME218827	0.76	1.07	0.42	0.63	0.78	1.14	3.55	0.81
12,13-DiHODE	ME218804	0.96	1.45	NA	0.40	0.72	0.86	NA	2.86
TXB2	ME218787	0.87	1.17	NA	0.59	0.79	1.04	1.32	1.58
9,10-DiHOME	ME218802	0.54	1.22	0.28	1.51	0.73	1.07	1.07	1.32
PGF2alpha	ME218794	0.71	0.91	0.33	1.20	0.88	1.17	1.30	1.64
12S-HETE	ME218824	0.88	1.13	0.64	0.72	0.99	1.09	0.99	0.91
15-deoxy PGJ2	ME218792	0.88	0.99	0.94	0.92	0.95	1.05	1.32	1.26
11,12-EpETrE	ME218848	1.12	0.90	0.86	1.02	1.17	0.90	0.98	0.99
8,9-DiHETrE	ME218808	1.01	1.11	0.71	1.15	0.78	1.00	1.08	0.97
9,10-e-DiHO	ME218800	0.72	1.18	1.24	1.22	0.90	1.00	0.87	1.10
11,12-DiHETrE	ME218807	0.89	1.14	1.01	1.12	0.97	0.93	0.95	0.97
14,15-DiHETrE	ME218806	0.93	1.11	0.98	1.09	0.98	0.96	0.89	0.89
9,10-DiHODE	ME218805	0.62	1.57	0.08	1.27	0.72	0.74	0.76	1.04
14-HDoHE	ME218834	0.93	1.32	0.35	0.56	1.09	1.02	0.50	0.54
12_13-DiHOME	ME218801	0.80	1.12	NA	0.80	1.20	1.07	0.80	0.80
12S-HEPE	ME218830	0.69	1.05	0.26	0.97	1.21	1.22	0.69	0.52
15-HEPE	ME218829	0.88	1.14	0.24	1.20	0.75	1.17	1.33	0.46
17-HDoHE	ME218833	0.97	1.14	0.30	0.92	0.92	1.02	1.59	0.58
4-HDoHE	ME218835	1.03	1.15	0.28	1.00	0.97	0.94	1.40	0.57
12(13)-EpOME	ME218842	0.62	1.20	0.27	1.03	1.12	0.97	1.23	1.02
alpha-12(13)-EpODE	ME218846	0.54	1.33	0.25	1.16	0.99	1.04	1.08	0.72
9-HOTE	ME218821	0.76	1.35	0.27	1.46	0.82	0.91	1.08	0.62
19,20-DiHDPE	ME218812	1.00	1.22	0.42	1.15	0.87	0.98	0.77	0.59
5S-HEPE	ME218832	1.02	1.15	0.32	1.38	0.77	1.07	0.59	0.54
9-HEPE	ME218831	0.97	1.15	0.29	1.30	0.76	1.12	0.81	0.52
15,16-DiHODE	ME218803	0.90	0.96	0.30	1.54	0.81	1.14	0.88	0.87
5,6-DiHETrE	ME218809	0.86	1.22	0.33	1.17	0.85	0.98	0.90	0.94
14,15-DiHETE	ME218811	0.79	1.07	0.46	1.18	0.87	1.22	1.00	0.62
17,18-DiHETE	ME218810	0.81	1.05	0.48	1.29	0.85	1.19	0.96	0.71
17(18)-EpETE	ME218850	0.67	1.38	NA	NA	0.63	1.18	1.52	0.56
9,10-EpO	ME218840	0.64	0.99	1.27	1.48	0.89	0.93	2.18	1.40
9(10)-EpOME	ME218843	0.60	1.20	0.36	0.84	1.00	0.94	2.04	1.33
9,12,13-TriHOME	ME218797	0.68	1.12	0.77	1.12	0.89	0.97	1.89	1.31
15-HETE	ME218823	0.89	1.12	0.55	0.82	0.88	1.05	1.68	0.96
PGE1	ME218789	0.84	0.95	0.87	0.98	1.09	0.98	2.02	0.76
PGD2	ME218791	0.83	1.24	NA	0.52	0.59	1.01	2.43	0.60
13-HOTE	ME218820	0.61	1.35	0.22	0.91	0.69	1.05	2.34	0.94
5-KETE	ME218839	1.04	0.99	0.53	0.60	0.86	1.09	2.53	0.79
6-trans-LTB4	ME218815	0.82	1.21	0.46	0.55	1.01	0.99	2.05	0.84
5-HETE	ME218828	0.91	1.11	0.49	0.82	0.89	0.98	2.28	0.90
8S-HETE	ME218825	0.85	1.13	0.47	0.79	0.86	1.02	2.31	0.91

Factors:

F1	CaseStatus:Case \| SEX:Female \| AGE_DICH:20_50
F2	CaseStatus:Case \| SEX:Female \| AGE_DICH:over50
F3	CaseStatus:Case \| SEX:Male \| AGE_DICH:20_50
F4	CaseStatus:Case \| SEX:Male \| AGE_DICH:over50
F5	CaseStatus:Control \| SEX:Female \| AGE_DICH:20_50
F6	CaseStatus:Control \| SEX:Female \| AGE_DICH:over50
F7	CaseStatus:Control \| SEX:Male \| AGE_DICH:20_50
F8	CaseStatus:Control \| SEX:Male \| AGE_DICH:over50

Data matrix